TY - JOUR
T1 - Mitral Valve Surgery After Transcatheter Edge-to-Edge Repair
T2 - Mid-Term Outcomes From the CUTTING-EDGE International Registry
AU - CUTTING-EDGE Investigators
AU - Kaneko, Tsuyoshi
AU - Hirji, Sameer
AU - Zaid, Syed
AU - Lange, Rudiger
AU - Kempfert, Jörg
AU - Conradi, Lenard
AU - Hagl, Christian
AU - Borger, Michael A.
AU - Taramasso, Maurizio
AU - Nguyen, Tom C.
AU - Ailawadi, Gorav
AU - Shah, Ashish S.
AU - Smith, Robert L.
AU - Anselmi, Amedeo
AU - Romano, Matthew A.
AU - Ben Ali, Walid
AU - Ramlawi, Basel
AU - Grubb, Kendra J.
AU - Robinson, Newell B.
AU - Pirelli, Luigi
AU - Chu, Michael W.A.
AU - Andreas, Martin
AU - Obadia, Jean Francois
AU - Gennari, Marco
AU - Garatti, Andrea
AU - Tchetche, Didier
AU - Nazif, Tamim M.
AU - Bapat, Vinayak N.
AU - Modine, Thomas
AU - Denti, Paolo
AU - Tang, Gilbert H.L.
AU - Vitanova, Keti
AU - Krane, Markus
AU - Akansel, Serdar
AU - Bhadra, Oliver D.
AU - Saha, Shekhar
AU - Bagaev, Erik
AU - Noack, Thilo
AU - Fahr, Florian
AU - Ascione, Guido
AU - Tagliari, Ana Paula
AU - Pizano, Alejandro
AU - Donatelle, Marissa
AU - Goel, Kashish
AU - Squiers, John J.
AU - Shah, Pinak B.
AU - Leurent, Guillaume
AU - Corbineau, Herve
AU - Asgar, Anita W.
AU - Demers, Philippe
AU - Pellerin, Michel
AU - Bouchard, Denis
AU - Ruaengsri, Chawannuch
AU - Wang, Lin
AU - Petrossian, George A.
AU - Kliger, Chad A.
AU - Leroux, Lionel
AU - Algadheeb, Muhanad
AU - Lavi, Shahar
AU - Werner, Paul
AU - Flagiello, Michele
AU - Bartorelli, Antonio L.
AU - Ghattas, Angie
AU - Dumonteil, Nicholas
AU - von Ballmoos, Moritz Wyler
AU - Atkins, Marvin D.
AU - D'Onofrio, Augusto
AU - Tessari, Chiara
AU - Geirsson, Arnar
AU - Kaple, Ryan K.
AU - Massi, Francesco
AU - Triggiani, Michele
AU - Van Belle, Eric
AU - Vincent, Flavien
AU - Denimal, Tom
AU - Brinkmann, Christina
AU - Schöfer, Joachim
AU - Di Eusanio, Marco
AU - Capestro, Filippo
AU - Estevez-Loureiro, Rodrigo
AU - Pinon, Miguel A.
AU - Kleiman, Neal S.
AU - Reardon, Michael J.
AU - Szerlip, Molly I.
AU - DiMaio, J. Michael
AU - Mack, Michael J.
AU - Lim, D. Scott
AU - Falk, Volkmar
AU - Maisano, Francesco
AU - George, Isaac
AU - Hahn, Rebecca T.
N1 - Funding Information:
Dr Kaneko is a speaker for Edwards Lifesciences, Medtronic, Abbott, and Baylis Medical; and is a consultant for 4C Medical. Dr Lange is an advisory board member for and has received royalties and speaker honoraria from Medtronic; has received speaker honoraria from Abbott; and is a shareholder in Highlife. Dr Kempfert has served as a physician proctor for Abbott, Boston Scientific, Edwards Lifesciences, and Medtronic. Dr Conradi is a physician proctor, consultant, and speaker for Edwards Lifesciences and Medtronic. Dr Hagl has received speaker honoraria from Edwards Lifesciences. Dr Borger has received speaker honoraria and/or consulting fees to his hospital from Edwards Lifesciences, Medtronic, Abbott, and CryoLife. Dr Taramasso has been a consultant for Abbott Vascular, Boston Scientific, Edwards Lifesciences, 4Tech, Mitraltech, Simulands, MTEx, Occlufit, CoreMedic, and Shenqi Medical. Dr Nguyen has received speaker honoraria from Edwards Lifesciences, CryoLife, and Abbott. Dr Ailawadi is a consultant for Abbott, Edwards Lifesciences, Medtronic, and AtriCure. Dr Smith has received grant support from Edwards Lifesciences; and has received speaker honoraria from Edwards Lifesciences, Abbott, and CryoLife. Dr Anselmi is a physician proctor and consultant for Abbott and Edwards Lifesciences. Dr Ben Ali has received research grants from Edwards Lifesciences and Medtronic. Dr Ramlawi is a consultant for Boston Scientific, Medtronic, LivaNova, and Atricure. Dr Grubb is a physician proctor for Medtronic, Edwards Lifesciences, and Boston Scientific; and has served as a consultant for Medtronic, Boston Scientific, Ancora, HLT, and BioVentrics. Dr Pirelli is a physician proctor for and has received speaker honoraria from Edwards Lifesciences; and is a consultant for Medtronic. Dr Chu has received speaker honoraria from Medtronic, Edwards Lifesciences, and Terumo Aortic. Dr Andreas is a physician proctor and consultant for and has received speaker honoraria from Edwards Lifesciences, Abbott, and Medtronic; and has received institutional research grants from Edwards Lifesciences, Abbott, Medtronic, and LSI Solutions. Dr Obadia is a consultant for Abbott, Carmat, Delacroix-Chevalier, Landanger, and Medtronic. Dr Gennari is a consultant for Medtronic. Dr Garatti is a physician proctor for Abbott. Dr Nazif has equity in Venus Medtech; and has received consulting fees or honoraria from Keystone Heart, Edwards Lifesciences, Medtronic, and Boston Scientific. Dr Bapat has served as a consultant for Medtronic, Edwards Lifesciences, 4C Medical, and Boston Scientific. Dr Modine is a physician proctor and consultant for Medtronic, Edwards Lifesciences, and Abbott. Dr Denti receives speaker honoraria from Abbott and Edwards Lifesciences; and is a consultant for InnovHeart. Dr Tang is a physician proctor for Medtronic; is a consultant for Medtronic, NeoChord, and Abbott; and is a physician advisory board member for Abbott and JenaValve. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Publisher Copyright:
© 2021 American College of Cardiology Foundation
PY - 2021/9/27
Y1 - 2021/9/27
N2 - Objectives: The aim of this study was to determine clinical and echocardiographic characteristics, mechanisms of failure, and outcomes of mitral valve (MV) surgery after transcatheter edge-to-edge repair (TEER). Background: Although >100,000 mitral TEER procedures have been performed worldwide, longitudinal data on MV surgery after TEER are lacking. Methods: Data from the multicenter, international CUTTING-EDGE registry were retrospectively analyzed. Clinical and echocardiographic outcomes were evaluated. Median follow-up duration was 9.0 months (interquartile range [IQR]: 1.2-25.7 months) after MV surgery, and follow-up was 96.1% complete at 30 days and 81.1% complete at 1 year. Results: From July 2009 to July 2020, 332 patients across 34 centers underwent MV surgery after TEER. The mean age was 73.8 ± 10.1 years, median Society of Thoracic Surgeons risk for MV repair at initial TEER was 4.0 (IQR: 2.3-7.3), and primary/mixed and secondary mitral regurgitation were present in 59.0% and 38.5%, respectively. The median interval from TEER to surgery was 3.5 months (IQR: 0.5-11.9 months), with overall median Society of Thoracic Surgeons risk of 4.8% for MV replacement (IQR: 2.8%-8.4%). The primary indication for surgery was recurrent mitral regurgitation (33.5%), and MV replacement and concomitant tricuspid surgery were performed in 92.5% and 42.2% of patients, respectively. The 30-day and 1-year mortality rates were 16.6% and 31.3%, respectively. On Kaplan-Meier analysis, the actuarial estimates of mortality were 24.1% at 1 year and 31.7% at 3 years after MV surgery. Conclusions: In this first report of the CUTTING-EDGE registry, the mortality and morbidity risks of MV surgery after TEER were not negligible, and only <10% of patients underwent MV repair. These registry data provide valuable insights for further research to improve these outcomes.
AB - Objectives: The aim of this study was to determine clinical and echocardiographic characteristics, mechanisms of failure, and outcomes of mitral valve (MV) surgery after transcatheter edge-to-edge repair (TEER). Background: Although >100,000 mitral TEER procedures have been performed worldwide, longitudinal data on MV surgery after TEER are lacking. Methods: Data from the multicenter, international CUTTING-EDGE registry were retrospectively analyzed. Clinical and echocardiographic outcomes were evaluated. Median follow-up duration was 9.0 months (interquartile range [IQR]: 1.2-25.7 months) after MV surgery, and follow-up was 96.1% complete at 30 days and 81.1% complete at 1 year. Results: From July 2009 to July 2020, 332 patients across 34 centers underwent MV surgery after TEER. The mean age was 73.8 ± 10.1 years, median Society of Thoracic Surgeons risk for MV repair at initial TEER was 4.0 (IQR: 2.3-7.3), and primary/mixed and secondary mitral regurgitation were present in 59.0% and 38.5%, respectively. The median interval from TEER to surgery was 3.5 months (IQR: 0.5-11.9 months), with overall median Society of Thoracic Surgeons risk of 4.8% for MV replacement (IQR: 2.8%-8.4%). The primary indication for surgery was recurrent mitral regurgitation (33.5%), and MV replacement and concomitant tricuspid surgery were performed in 92.5% and 42.2% of patients, respectively. The 30-day and 1-year mortality rates were 16.6% and 31.3%, respectively. On Kaplan-Meier analysis, the actuarial estimates of mortality were 24.1% at 1 year and 31.7% at 3 years after MV surgery. Conclusions: In this first report of the CUTTING-EDGE registry, the mortality and morbidity risks of MV surgery after TEER were not negligible, and only <10% of patients underwent MV repair. These registry data provide valuable insights for further research to improve these outcomes.
KW - mitral valve replacement
KW - mitral valve surgery
KW - transcatheter edge-to-edge repair
UR - http://www.scopus.com/inward/record.url?scp=85114663034&partnerID=8YFLogxK
U2 - 10.1016/j.jcin.2021.07.029
DO - 10.1016/j.jcin.2021.07.029
M3 - Article
C2 - 34556275
AN - SCOPUS:85114663034
SN - 1936-8798
VL - 14
SP - 2010
EP - 2021
JO - JACC: Cardiovascular Interventions
JF - JACC: Cardiovascular Interventions
IS - 18
ER -